The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.
 
Neal D. Shore
Employment - GenesisCare
Leadership - Alessa Therapeutics; Photocure
Consulting or Advisory Role - Abbvie; AIkido Pharma; Amgen; Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clarity Pharmaceuticals; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Guardant Health; ImmunityBio; Incyte; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myovant Sciences; Myriad Genetics; NGM Biopharmaceuticals; Nonagen Bioscience; Novartis; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Photocure; PlatformQ Health; Profound Medical; Promaxo; Propella Therapeutics; Protara Therapeutics; Sanofi; Sesen Bio; Speciality Networks; Telix Pharmaceuticals; Tempus; Tolmar; Urogen pharma; Vaxiion; Vessi Medical
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
Expert Testimony - Ferring
Other Relationship - Alessa Therapeutics; Photocure
 
Jose W. Avitia
No Relationships to Disclose
 
James L. Bailen
Consulting or Advisory Role - Astellas Pharma; Auxilium; Bayer; Dendreon
Speakers' Bureau - Astellas Pharma; Auxilium; Bayer; Valeant/Dendreon
Research Funding - Astellas Pharma; Bayer; Dendreon (Inst); Janssen (Inst); Medivation (Inst); Millenium Pharamceuticals
 
Luke T. Nordquist
No Relationships to Disclose
 
William Richardson
No Relationships to Disclose
 
Cody J. Peer
No Relationships to Disclose
 
William Douglas Figg
Research Funding - Astellas Pharma (Inst); Biocompatibles (Inst); Celgene (Inst); Nerviano Medical Sciences (Inst); NovaRX (Inst); Pfizer (Inst); Propella Therapeutics (Inst); TRACON Pharma (Inst)
 
Jacqueline M. Walling
Leadership - Arch Oncology; Nurix; Plexxikon
Consulting or Advisory Role - Aduro Biotech; Ambagon Therapeutics; Aminex; Arch Oncology; Aro Biotherapeutics; CytomX Therapeutics; Flag Therapeutics; Harpoon Therapeutics; January Therapeutics; Janux Therapeutics; Myovant Sciences; Nurix; Nuvation Bio; Oryzon Genomics; Plexxikon; Propella Therapeutics; Prothena; Proximagen; QUE Oncology; Que Oncology; Rhizen Pharmaceuticals; Sesen Bio; ShapeTx; Stealth Biotherapeutics; TRex Bio; Upsher-Smith
Expert Testimony - Puma Biotechnology
 
Joel Robert Eisner
Employment - GeneCentric
Stock and Other Ownership Interests - GeneCentric; Innocrin Pharma
Consulting or Advisory Role - Propella Therapeutics
Patents, Royalties, Other Intellectual Property - Provisional patents for GeneCentric and Innocrin Pharma as part of my employments
 
Matthew Sharp
Employment - Propella Therapeutics; Vizuri
Stock and Other Ownership Interests - Propella Therapeutics
Patents, Royalties, Other Intellectual Property - Patent applications in progress with Propella Therapeutics
Travel, Accommodations, Expenses - Propella Therapeutics
 
Robert J. Schotzinger
Leadership - Propella Therapeutics
 
William R. Moore
Employment - Propella Therapeutics; Vizuri
Leadership - Propella Therapeutics; Vizuri
Stock and Other Ownership Interests - Propella Therapeutics; Vizuri
Research Funding - Propella Therapeutics; Vizuri
Patents, Royalties, Other Intellectual Property - I'm an inventor on patents that were assigned to Propella Therapeutics that protect composition of matter, methods of use, and manufacturing of abiraterone decanoate
Travel, Accommodations, Expenses - Propella Therapeutics; Vizuri
 
Ronald F. Tutrone
Employment - Chesapeake Urology
Stock and Other Ownership Interests - Compass Therapeutics; GlaxoSmithKline; Myovant Sciences; Novartis; Nymox; Veru
Consulting or Advisory Role - Exosome Diagnostics; Myovant Sciences; Novartis; Nymox
Speakers' Bureau - Exosome Diagnostics; Medivation/Astellas; Pfizer
Research Funding - Advantagene (Inst); Bayer (Inst); Dendreon (Inst); Exosome Diagnostics (Inst); Genomic Health (Inst); Janssen Oncology (Inst); MDxHealth (Inst); Medivation/Astellas (Inst); Merck (Inst); POINT Biopharma (Inst); Veru (Inst)